[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100567504":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":10,"responsibleParty":31,"collaborators":33,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":45,"sex":46,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":52,"studyType":53,"phases":10,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":64,"whyStopped":10,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":70,"leadSponsor":72,"locationsCount":10},{"fullName":5,"class":6},"Orchidia pharmaceutical Industries","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"1 arm group, pregnant non-anemic females, second trimester.",null,"Liposomal iron, capsules, 1 Capsule with food or few hours before or after taking other medication once daily. 1 arm group, Participants in this study will receive a daily oral dose of 30 mg Iron for a duration of 90 days. The liposomal formulation is designed to enhance the bioavailability of iron, potentially reducing gastrointestinal side effects.",[13],"Dietary Supplement: 30 mg liposomal iron, capsules",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DIETARY_SUPPLEMENT","30 mg liposomal iron, capsules","a dietary supplement capsule, of mainly 30 mg liposomal iron, and Vitamin C 70mg, vitamin D3 400IU, vitamin B6 1.75 mcg, Folate 1000 mcg, b=vitamin B12 10 mcg. all in capsulated in 1 Hard gelatin capsule",[9],[21],{"name":22,"affiliation":23,"role":24},"Yasser S El Kassar, Prof. Dr.","Faculty of medicine Alexandria university, obstetrics and gynecology department","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":10,"email":30},"Nada K Rezk, Medical Advisor","CONTACT","+201000071245","nadakamel233@gmail.com",{"type":32,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[34],{"name":35,"class":36},"MARS-Global","OTHER","100567504","liposomal-iron-30-mg-supplement-in-non-anemic-pregnant-females-100567504",false,"NCT06669052","Liposomal Iron 30 mg Supplement in Non-anemic Pregnant Females","Liposomal Iron 30 mg Supplement in Non-anemic Pregnant Females an Observational Study","LITSNPF","Inclusion Criteria:\n\n* Pregnant females; gestational age from 14 to 16 weeks Age 18-45 years\n* Low-risk pregnancy is defined as a pregnancy in which there is no high risk of problems or unfavorable outcomes, and the expectant mother and fetus are typically healthy\n* Non-anemic women at the time of recruitment (hemoglobin level not less than 10.5. Hemoglobin measured within 2 or 3 weeks of recruitment\n* Singleton pregnancy\n* Agree to participate in the study including data collection from medical records and participation in related questionnaires.\n\nExclusion Criteria:\n\n* Inadequate medical records\n* Pregnant women living in areas away from the recruitment center\n* Had any chronic health problem.\n* Women with any form of hereditary anemia including sickle cell anemia, thalassemia, and Glucose-6-phosphate dehydrogenase (G6PD) deficiency.\n* History of antepartum bleeding\n* Refuse to sign the informed consent.",true,"FEMALE","18 Years","45 Years",{"count":50,"type":51},714,"ESTIMATED","90 Days","OBSERVATIONAL","Protocol Summary: Liposomal Iron Supplementation in Non-anemic Pregnant Females This observational study aims to evaluate the efficacy and safety of daily liposomal iron supplementation (30 mg) in non-anemic pregnant women during their second trimester of pregnancy. The study will focus on pregnant females aged 18-45 years with low-risk, singleton pregnancies who are non-anemic (hemoglobin ≥10.5) at 14-16 weeks gestation.\n\nPrimary Research Question:\n\nDoes daily supplementation with 30 mg liposomal iron effectively maintain maternal hemoglobin levels over 90 days? Measured by: The difference in maternal hemoglobin levels between baseline and after 90 days of treatment in women recruited at 14-16 weeks gestation.\n\nSecondary Research Questions:\n\nWhat are the effects of liposomal iron supplementation on serum ferritin levels? Measured by: Changes in serum ferritin levels between baseline and after 90 days of treatment.\n\nWhat is the safety profile of liposomal iron supplementation during pregnancy? Measured by: Maternal gastrointestinal side effects monitored at each prenatal visit (day 30, 60, and 90).\n\nWhat is the compliance rate with liposomal iron supplementation? Measured by: Participant-reported compliance assessed at each prenatal visit (day 30, 60, and 90).\n\nParticipants will:\n\nReceive daily liposomal iron supplementation (30 mg) for 90 days. Attend regular prenatal visits for monitoring at days 30, 60, and 90. Complete questionnaires about compliance and any adverse effects at each visit. Undergo blood tests to measure hemoglobin and serum ferritin levels at baseline and day 90.\n\nThis multi-center study will involve 714 participants across 100 sites, with recruitment beginning in November 2024 and study completion expected by July 2025. The study's findings will contribute to understanding the role of liposomal iron supplementation in preventing iron deficiency during pregnancy and its potential advantages over traditional iron supplements in terms of tolerability and compliance.",[56,57],"Anemia of Pregnancy","Iron Deficiency Anemia",[59,60,61,62,63],"30 mg liposomal irom","non-anemic pregnant females","observational study","hemoglobin level","Second trimester","NOT_YET_RECRUITING","2024-10-31",{"date":67,"type":68},"2024-11-01","ACTUAL",{"date":67,"type":51},{"date":71,"type":51},"2025-05",{"name":5,"class":6}]